Rhode Island feeling effects of Amgen cuts

Rhode Island officials are getting used to the idea that the state no longer figures prominently in Amgen's future plans. The biotech giant is cutting hundreds of jobs at a manufacturing facility in the state, and plenty of spare capacity at other manufacturing sites makes Rhode Island an unlikely candidate to produce any new drugs for the company. An undisclosed number of Amgen employees in the state had already accepted early buyouts, raising the impact of the biotech's restructuring.

- check out the report on Amgen

Related Articles:
At corporate HQ, Amgen drops the axe. Report
Amgen discusses the future with analysts. Report
Amgen makes big workforce, budget cuts. Report
Major challenges loom for Amgen. Report
Amgen in crisis? Not us, says CEO Sharer. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.